Hoth Therapeutics Announces IRB Approval For FDA Cleared First-In-Human Clinical Trial Of HT-001 At Second Clinical Site
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics (NASDAQ:HOTH) has received IRB approval from the University of Texas MD Anderson Cancer Center to proceed with its First-in-Human Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with EGFRi. This is the second site approved to host the trial.
June 14, 2023 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hoth Therapeutics has received IRB approval for its Phase 2a clinical trial of HT-001 at the second site, potentially bringing the company closer to a successful treatment for skin toxicities associated with EGFRi.
The IRB approval for Hoth Therapeutics' Phase 2a clinical trial of HT-001 at the second site is a positive development for the company. This milestone brings HOTH closer to potentially having a successful treatment for skin toxicities associated with EGFRi, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100